Extracellular amino acid levels in hippocampus during pilocarpine-induced seizures

doi:10.1016/0920-1211(93)90018-3

Epilepsy Research

Volume 14, Issue 2, February 1993, Pages 139-148

https://doi.org/10.1016/0920-1211(93)90018-3 Get rights and content

Abstract

Extracellular levels of aspartate, glutamate and glutamine were monitored by microdialysis in the dorsal hippocampus of freely moving rats following the administration of a convulsant dose of pilocarpine (400 mg/kg,i.p.). Rats were either pretreated with the glutamate uptake inhibitor, l-trans-pyrrolidine-2,4-dicarboxylic acid (PDC, 1 mM in the perfusion medium, -25 min), or received pilocarpine directly. All rats injected with pilocarpine (with or without PDC pretreatment) developed limbic seizures (latency 15.4∓2.4 min). Without PDC pretreatment there were no significant changes in extracellular levels of aspartate, glutamate and glutamine following pilocarpine administration until the onset of limbic seizures when glutamine levels fell by 35%. Following PDC pretreatment there were large and sustained increases in extracellular hippocampal aspartate (250%) and glutamate (55%) levels, but no significant change in the glutamine level. When pilocarpine was administered to this group of rats, there were further selective, significant, transient increases in the extracellular levels of aspartate (31%) and glutamate (18%) which preceded the onset of seizures. Aspartate and glutamate levels were not significantly increased (relative to PDC controls) during seizures.

The conditions for pilocarpine-induced increases in aspartate and glutamate release were established in parallel groups of anaesthetised rats were pilocarpine was administered via a microdialysis probe in the dorsal hippocampus. Following the infusion of 10 mM pilocarpine there were llarge and rapid increases in the levels of aspartate (143%) and glutamate (179%), which were completely abolished by the absence of calcium in the perfusion medium, or by the presence of atropine (20 mM) or tetrodotoxin (1 μM).

References (39)

J.P. Chandler et al.
The septohippocampal projections in the rat: an electron microscopic horseradish peroxidase study
Neuroscience
(1983)
A.E. Cole et al.
The pharmacology of cholinergic excitatory responses in hippocampal pyramidal cells
Brain Res.
(1984)
J.V. Halliwell et al.
Voltage-clamp analysis of muscarinic excitation in hippocampal neurones
Brain Res.
(1982)
K. Krnjevic et al.
Electrophysiological and pharmacological characteristics of facilitation of hippocampal population spikes by stimulation of medial septum
Neuroscience
(1982)
K. Krnjevic et al.
Septohippocampal disinhibition
Brain Res.
(1988)
G. Lallement et al.
Effects of soman-induced seizures on different extracellular amino acid levels and on glutamate uptake in rat hippocampus
Brain Res.
(1991)
A. Lehmann
Alterations in hippocampal extracellular amino acids and purine catabolites during limbic seizures induced by folate injections into the rabbit amigdala
Neuroscience
(1987)
A. Lehmann et al.
Effect of status epilepticus on extracellular amino acids in the hippocampus
Brain Res.
(1985)
M. Marchi et al.
Muscarinic inhibition of endogenous glutamate release from rat hippocampus synaptosomes
Neurosci. Lett.
(1989)
H. Markram et al.
Acetylcholine potentiates responses to $N- methyl- d -aspartate$ in the rat hippocampus
Neurosci. Lett.
(1990)

M.P. Mattson

Acetylcholine potentiates glutamate-induced neurodegeneration in cultured hippocampal neurones

Brain Res.

(1989)

B.S. Meldrum

Excitotoxicity and epileptic brain damage

Epilepsy Res.

(1991)

M.H. Millan et al.

Changes in rat brain extracellular glutamate concentration during seizures induced by systemic picrotoxin or focal bicuculline injection: An in vivo dialysis study with on-line enzymatic detection

Epilepsy Res.

(1991)

D. Nicholls et al.

The release and uptake of excitatory amino acids

Trends Pharmacol. Sci.

(1990)

M. Raiteri et al.

Endogenous aspartate release in the rat hippocampus is inhibited by M2 ‘cardiac’ muscarinic receptors

Eur. J. Pharmacol.

(1990)

D.G. Spencer et al.

Direct autoradiographic determination of M1 and M2 muscarinic acetylcholine receptor distribution in the rat brain: Relation to cholinergic nuclei and projections

Brain Res.

(1986)

M.D. Tricklebank et al.

Evidence that a proconvulsant action of lithium is mediated by inhibition of myo-inositol phosphatase in mouse brain

Brain Res.

(1991)

W.A. Turski et al.

Limbic seizures produced by pilocarpine in rats: behavioural, electroencephalographic and neuropathological study

Behav. Brain Res.

(1983)

N.J. Woolf et al.

Cholinergic systems in the rat brain: I. Projections to the limbic telencephalon

Brain Res. Bull.

(1984)

Cited by (112)

Brain network properties of clinical versus subclinical seizures among critically ill children
2023, Clinical Neurophysiology
Electrographic seizures are common among critically ill children, and have been associated with worse outcomes. Despite their often-widespread cortical representation, most of these seizures remain subclinical, a phenomenon which remains poorly understood. We compared the brain network properties of clinical versus subclinical seizures to gain insight into their relative potential deleterious effects.
Functional connectivity (phase lag index) and graph measures (global efficiency and clustering coefficients) were computed for 2178 electrographic seizures recorded during 48-hours of 19-channel continuous EEG monitoring obtained in 20 comatose children. Frequency-specific group differences in clinical versus subclinical seizures were analyzed using a non-parametric ANCOVA, adjusting for age, sex, medication exposure, treatment intensity and seizures per subject.
Clinical seizures demonstrated greater functional connectivity than subclinical seizures at alpha frequencies, but less connectivity than subclinical seizures at delta frequencies. Clinical seizures also demonstrated significantly higher median global efficiency than subclinical seizures (p < 0.01), and significantly higher median clustering coefficients across all electrodes at alpha frequencies.
Clinical expression of seizures correlates with greater alpha synchronization of distributed brain networks.
The stronger global and local alpha-mediated functional connectivity observed during clinical seizures may indicate greater pathological network recruitment. These observations motivate further studies to investigate whether the clinical expression of seizures may influence their potential to cause secondary brain injury.
Pretreatment with a glutamine synthetase inhibitor MSO delays the onset of initial seizures induced by pilocarpine in juvenile rats
2021, Brain Research
The contribution of glutamatergic transmission to generation of initial convulsive seizures (CS) is debated. We tested whether pretreatment with a glutamine synthetase (GS) inhibitor, methionine sulfoximine (MSO), affects the onset and progression of initial CS by cholinergic stimulus in juvenile rats. Male rats (24 days old, Sprague Dawley) sequentially received i.p. injections of lithium-carbonate, MSO, methyl-scopolamine, and pilocarpine (Pilo). Pilo was given 150 min after MSO. Animals were continuously monitored using the Racine scale, EEG/EMG and intrahippocampal glutamate (Glu) biosensors. GS activity as measured in hippocampal homogenates, was not altered by MSO at 150 min, showed initial, varied inhibition at 165 (15 min post-Pilo), and dropped down to 11% of control at 60 min post-Pilo, whereas GS protein expression remained unaltered throughout. Pilo did neither modulate the effect of MSO on GS activity nor affect GS activity itself, at any time point. MSO reduced from 32% to 4% the number of animals showing CS during the first 12 min post-Pilo, delayed by ~6 min the appearance of electrographic seizures, and tended to decrease EMG power during ~15 min post-Pilo. The results indicate that MSO impairs an aspect of glutamatergic transmission involved in the transition from the first cholinergic stimulus to the onset of seizures. A continuous rise of extracellular Glu lasting 60 min was insignificantly affected by MSO, leaving the nature of the Glu pool(s) involved in altered glutamatergic transmission undefined.
Proteomic profiling of sclerotic hippocampus revealed dysregulated packaging of vesicular neurotransmitters in temporal lobe epilepsy
2020, Epilepsy Research
Temporal lobe epilepsy (TLE) is the most common type of epilepsy. Hippocampal sclerosis is the most distinctive pathological feature of TLE; however, its role in the pathogenesis of TLE remains to be clarified. We performed global protein expression analysis of hippocampus from TLE patients and controls, aiming to reveal the molecular signaling pathways related to TLE.
Proteomic and bioinformatic analyses of the hippocampus were performed on 4 TLE and 4 control samples. High-resolution liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS), in combination with TMT-6plex quantification, was applied for global protein expression analysis. The proteomics results were validated by Western blot with 25 TLE and 25 control individuals and Immunohistochemistry analysis with 33 TLE and 10 control individuals.
Bioinformatics analysis demonstrated differentially expressed proteins in the synaptic vesicle pathway, the prostaglandin synthesis and regulation pathway and endocannabinoids and retrograde modulation of synaptic transmission pathway. Among these, excitatory amino acid transporter 1 (EAAT1) and Vesicular glutamate transporter 1 (VGLUT1) are critical for TLE and dysregulated expression might be closely related to the uptake of extracellular glutamate and contribute to the pathophysiology of TLE. Ras-related protein Rab-3A (RAB3A) downregulation might indicate the TLE-induced compensatory deficit in glutamate release.
Our study indicates that expression of some proteins involved in the packaging of vesicular neurotransmitters is altered in TLE. In addition, upregulated expression of annexin family proteins, which are also related to TLE, might play an important role in protection against TLE.
Neonatal Seizures
2018, Volpe's Neurology of the Newborn
Seizures represent the most distinctive and frequent manifestations of neurological disease in the neonatal period. Compared with seizures in older patients, neonatal seizures have different clinical appearances, electrographic characteristics, etiologies, and management approaches. Because most neonatal seizures are acute symptomatic seizures occurring because of a brain insult or brain dysfunction, neonatal seizures indicate the presence of underlying disorders that may require specific therapy. Problematically, neonatal seizure diagnosis is difficult because the clinical manifestations of seizures may be subtle and difficult to reliably identify. Furthermore, most neonatal seizures are EEG-only (subclinical, nonconvulsive) and have no clinically evident manifestations. Thus, EEG monitoring plays an increasingly important role in neonatal seizure identification and management. Treatment of neonatal seizures is generally considered necessary because experimental and human evidence suggest seizures may lead to secondary brain injury and are associated with less favorable outcomes. However, antiseizure medications may have associated risks, and there are few data to guide evidence-based management. This chapter reviews the pathophysiology and clinical aspects of neonatal seizures with emphasis on the influence of the developmental characteristics of the perinatal brain; viewed in this context, the manifestations, causes, and effects of neonatal seizures become more understandable.
Anticonvulsant activity, organotypic hippocampal neuroprotection assay and in-silico sodium channel blocking potential of 2-amino-6-nitrobenzothiazole derived semicarbazones
2017, Biomedicine and Pharmacotherapy
Epilepsy is one of the dreadful neurodegenerative disorder characterized by recurrent, unprovoked seizures. Currently available antiepileptic drugs are still associated with enormous side effects resulting in search of newer, more effective and safer agents. In view of this, we have investigated anticonvulsant activity of 2-amino-6-nitrobenzothiazole derived semicarbazones (7–32) in various in-vivo animal seizure models viz. maximal electroshock (MES), subcutaneous pentylenetetrazole (scPTZ) and 6 Hz psychomotor seizure model. Neurotoxicity was estimated by rotarod test. The compounds were also assessed for their neuroprotective potential from excitotoxic insult using organotypic hippocampal slice culture neuroprotection assay. Several compounds exhibited excellent anticonvulsant activity in MES and scPTZ models compared to reference drugs, phenytoin and levetiracetam. The results of kainic acid (KA) – induced neuroprotection assay indicated that compounds 26 and 24 were found to be most potent with IC₅₀ of 99.54 ± 1.27 and 101.00 ± 1.20 μM respectively. Both the compounds attenuated KA-mediated cell death in organotypic hippocampal slice cultures. Some of the compounds were found to be good antidepressants, better than the reference drug citalopram, when analyzed in forced swim test. Since semicarbazones exhibited profile resembling phenytoin, an attempt was made to screen them against human neuronal sodium channel isoform (hNa_v1.2) by performing computational molecular docking using AutoDock 4.2. Compound 30, 1-(5-Chloro-2-oxoindolin-3-ylidene)-4-(6-nitrobenzothiazol-2-yl)semicarbazide emerged as lead candidate possessing excellent in-vivo MES activity and high binding affinity computationally, better than the reference drug phenytoin and also exhibited neuroprotection from excitotoxic insult in KA-induced neuroprotection assay (IC₅₀ = 126.80 ± 1.24 μM). However, some of the active compounds were neurotoxic at their anticonvulsant doses. Further optimization studies are needed to reduce toxicity and develop them as novel therapeutic agents for epilepsy.
Amiodarone reduces depolarization-evoked glutamate release from hippocampual synaptosomes
2017, Journal of Pharmacological Sciences
Decreased brain glutamate level has emerged as a new therapeutic approach for epilepsy. This study investigated the effect and mechanism of amiodarone, an anti-arrhythmic drug with antiepileptic activity, on glutamate release in the rat hippocampus. In a synaptosomal preparation, amiodarone reduced 4-aminopyridine-evoked Ca²⁺-dependent glutamate release and cytosolic Ca²⁺ concentration elevation. Amiodarone did not affect the 4-aminopyridine-evoked depolarization of the synaptosomal membrane potential or the Na⁺ channel activator veratridine-evoked glutamate release, indicating that the amiodarone-mediated inhibition of glutamate release is not caused by a decrease in synaptosomal excitability. The inhibitory effect of amiodarone on 4-aminopyridine-evoked glutamate release was markedly decreased in synaptosomes pretreated with the Ca_v2.2 (N-type) and Ca_v2.1 (P/Q-type) channel blocker ω-conotoxin MVIIC, the calmodulin antagonists W7 and calmidazolium, or the protein kinase A inhibitors H89 and KT5720. However, the intracellular Ca²⁺-release inhibitors dantrolene and CGP37157 had no effect on the amiodarone-mediated inhibition of glutamate release. Furthermore, amiodarone reduced the frequency of miniature excitatory postsynaptic currents without affecting their amplitude in hippocampal slices. Our data suggest that amiodarone reduces Ca²⁺ influx through N- and P/Q-type Ca²⁺ channels, subsequently reducing the Ca²⁺-calmodulin/protein kinase A cascade to inhibit the evoked glutamate release from rat hippocampal nerve terminals.

View all citing articles on Scopus

View full text

Extracellular amino acid levels in hippocampus during pilocarpine-induced seizures

Abstract

Neuroscience

Brain Res.

Brain Res.

Neuroscience

Brain Res.

Brain Res.

Neuroscience

Brain Res.

Neurosci. Lett.

Neurosci. Lett.

Brain Res.

Epilepsy Res.

Epilepsy Res.

Trends Pharmacol. Sci.

Eur. J. Pharmacol.

Brain Res.

Brain Res.

Behav. Brain Res.

Brain Res. Bull.